NPO Petrovax Pharm, a leader among Russian pharmaceutical developers and manufacturers of innovative medicinal products, is proud to announce the arrival of Grippol® Plus vaccine in No 5 ampoules.
Grippol® Plus is a Russian-made, new-generation, inactivated influenza vaccine. An improved version of Grippol®, the drug is preservative-free and has proven effective and safe for both adults and children, as well as for special cases, including individuals with chronic somatic diseases and pregnant women.
NPO Petrovax Pharm registered the Grippol® Plus trademark in 2008. From 2009 the vaccine has been used for childhood vaccination in the National Priority Project “Health”. In 2011 alone, the company has supplied 12.2 million doses of the vaccine within the National Preventive Vaccination Calendar.
Until recently, Grippol® Plus was only available in single-dose syringes but, in the wake of the product's popularity, the demand rose for an ampoule version.
Like the syringe form, the ampoule presentation of Grippol® Plus is manufactured in compliance with the international GMP guidelines, retaining all the benefits of the original drug, namely:
It is also important to note that the ampoule presentation of the vaccine is more affordable than the syringe version, making it more cost-efficient for healthcare institutions, thereby predicating its considerable social impact on the Russian pharma market.
The ampoule presentation of Grippol® Plus has all the required compliance certificates, issued by Tarasevich State Scientific Research Institute of Standardisation and Control of Medical Biological Preparations under the Ministry of Health and Social Development of the Russian Federation, and is already widely available.